Structure-based design of a streptavidin mutant specific for an artificial biotin analogue

Journal of Biochemistry

Volumn 157, Issue 6, 2015, Pages 467-475

  Kawato, Tatsuya ^a   Mizohata, Eiichi ^a   Shimizu, Yohei ^b   Meshizuka, Tomohiro ^a   Yamamoto, Tomohiro ^b   Takasu, Noriaki ^b   Matsuoka, Masahiro ^c   Matsumura, Hiroyoshi ^a   Kodama, Tatsuhiko ^c   Kanai, Motomu ^b   Doi, Hirofumi ^c   Inoue, Tsuyoshi ^a   Sugiyama, Akira ^b,c  

^a OSAKA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Endogenous biotin; Molecular design; Pretargeting; Streptavidin; X ray structural analysis

Indexed keywords

AMINO ACID; BIOTIN DERIVATIVE; LISA 314; MUTANT PROTEIN; STREPTAVIDIN; UNCLASSIFIED DRUG; BIOTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; ESCHERICHIA COLI; IMMUNOGENICITY; NONHUMAN; SURFACE PLASMON RESONANCE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; METABOLISM; MUTATION; PROTEIN CONFORMATION; PROTON NUCLEAR MAGNETIC RESONANCE; X RAY CRYSTALLOGRAPHY;

BIOTIN; CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION; PROTON MAGNETIC RESONANCE SPECTROSCOPY; STREPTAVIDIN; SURFACE PLASMON RESONANCE;

EID: 84943613608     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvv004     Document Type: Article

References (48)

1. Reichert, J. M. and Valge-Archer, V. E. (2007) Development trends for monoclonal antibody cancer therapeutics. Nat. Rev. Drug Discov. 6, 349-356
2. Orcutt, K. D., Slusarczyk, A. L., Cieslewicz, M., Ruiz-Yi, B., Bhushan, K. R., Frangioni, J. V., and Wittrup, K. D. (2011) Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl. Med. Biol. 38, 223-233
3. Forero, A., Weiden, P. L., Vose, J. M., Knox, S. J., LoBuglio, A. F., Hankins, J., Goris, M. L., Picozzi, V. J., Axworthy, D. B., Breitz, H. B., Sims, R. B., Ghalie, R. G., Shen, S., and Meredith, R. F. (2004) Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood 104, 227-236
4. Zeglis, B. M., Sevak, K. K., Reiner, T., Mohindra, P., Carlin, S. D., Zanzonico, P., Weissleder, R., and Lewis, J. S. (2013) A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. J. Nucl. Med. 54, 1389-1396
5. Goldenberg, D. M., Chatal, J. F., Barbet, J., Boerman, O., and Sharkey, R. M. (2007) Cancer imaging and therapy with bispecific antibody pretargeting. Update Cancer Ther. 2, 19-31
6. Goodwin, D., Meares, C, Diamanti, C, McCall, M., Lai, C, Torti, F., McTigue, M., and Martin, B. (1984) Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins. Eur. J. Nucl. Med. 9, 209-215
7. Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., and Chatal, J. F. (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol. 24, 823-834
8. Boerman, O. C., van Schaijk, F. G., Oyen, W. J., and Corstens, F. H. (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J. Nucl. Med. 44, 400-411
9. Palanca-Wessels, M. C. and Press, O. W. (2014) Advances in the treatment of hematologic malignancies using immunoconjugates. Blood 123, 2293-2301
10. Press, O. W., Corcoran, M., Subbiah, K., Hamlin, D. K., Wilbur, D. S., Johnson, T., Theodore, L., Yau, E., Mallett, R., Meyer, D. L., and Axworthy, D. (2001) A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98, 2535-2543
11. Pagel, J. M., Hedin, N., Subbiah, K., Meyer, D., Mallet, R., Axworthy, D., Theodore, L. J., Wilbur, D. S., Matthews, D. C., and Press, O. W. (2003) Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 101, 2340-2348
12. Pantelias, A., Pagel, J. M., Hedin, N., Saganic, L., Wilbur, S., Hamlin, D. K., Wilbur, D. S., Lin, Y., Stone, D., Axworthy, D., Gopal, A. K., and Press, O. W. (2007) Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood 109, 4980-4987
13. Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F., Hobson, L. J., Beaumier, P. L., and Fritzberg, A. R. (2000) Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl Acad. Sci. USA. 97, 1802-1807
14. Zhang, M., Zhang, Z., Garmestani, K., Schultz, J., Axworthy, D. B., Goldman, C. K., Brechbiel, M. W., Carrasquillo, J. A., and Waldmann, T. A. (2003) Pretarget radiotherapy with an anti-CD25 antibodystreptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl. Acad. Sci. USA. 100, 1891-1895
15. Chang, C. H., Sharkey, R. M., Rossi, E. A., Karacay, H., McBride, W., Hansen, H. J., Chatal, J. F., Barbet, J., and Goldenberg, D. M. (2002) Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol. Cancer Ther. 1, 553-563
16. Green, N. M. (1975) Avidin. Adv. Protein Chem. 29, 85-133
17. Chaiet, L. and Wolf, F. J. (1964) The properties of streptavidin, a biotin-binding protein produced by streptomycetes. Arch. Biochem. Biophys. 106, 1-5
18. Diamandis, E. P. and Christopoulos, T. K. (1991) The biotin-(strept) avidin system: principles and applications in biotechnology. Clin. Chem. 37, 625-636
19. Voss, S. and Skerra, A. (1997) Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Streptag II peptide and improved performance in recombinant protein purification. Protein Eng. 10, 975-982
20. Korndorfer, I. P. and Skerra, A. (2002) Improved affinity of engineered streptavidin for the Strep-tag II peptide is due to a fixed open conformation of the lid-like loop at the binding site. Protein Sci. 11, 883-893
21. Schmidt, T. G. and Skerra, A. (2007) The Strep-tag system for one-step purification and high-affinity detection or capturing of proteins. Nat. Protoc. 2, 1528-1535
22. Paganelli, G., Chinol, M., Maggiolo, M., Sidoli, A., Corti, A., Baroni, S., and Siccardi, A. G. (1997) The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur. J. Nucl. Med. 24, 350-351
23. Meyer, D. L., Schultz, J., Lin, Y., Henry, A., Sanderson, J., Jackson, J. M., Goshorn, S., Rees, A. R., and Graves, S. S. (2001) Reduced antibody response to streptavidin through site-directed mutagenesis. Protein Sci. 10, 491-503
24. Forster, G. J., Santos, E. B., Smith-Jones, P. M., Zanzonico, P., and Larson, S. M. (2006) Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl. Med. 47, 140-149
25. Baker, H. (1985) Assessment of biotin status: clinical implications. Ann. N. Y. Acad. Sci. 447, 129-132
26. Knox, S. J., Goris, M. L., Tempero, M., Weiden, P. L., Gentner, L., Breitz, H, Adams, G. P., Axworthy, D., Gaffigan, S., Bryan, K., Fisher, D. R., Colcher, D., Horak, I. D., and Weiner, L. M. (2000) Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 6, 406-414
27. Yumura, K., Ui, M., Doi, H., Hamakubo, T., Kodama, T., Tsumoto, K., and Sugiyama, A. (2013) Mutations for decreasing the immunogenicity and maintaining the function of core streptavidin. Protein Sci. 22, 213-221
28. Reznik, G. O., Vajda, S., Sano, T., and Cantor, C. R. (1998) A streptavidin mutant with altered ligand-binding specificity. Proc. Natl. Acad. Sci. USA. 95, 13525-13530
29. Hamblett, K. J., Kegley, B. B., Hamlin, D. K., Chyan, M. K., Hyre, D. E., Press, O. W., Wilbur, D. S., and Stayton, P. S. (2002) A streptavidin-biotin binding system that minimizes blocking by endogenous biotin. Bioconjug. Chem. 13, 588-598
30. Park, S. I., Shenoi, J., Frayo, S. M., Hamlin, D. K., Lin, Y., Wilbur, D. S., Stayton, P. S., Orgun, N., Hylarides, M., Buchegger, F., Kenoyer, A. L., Axtman, A., Gopal, A. K., Green, D. J., Pagel, J. M., and Press, O. W. (2011) Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma. Clin. Cancer Res. 17, 7373-7382
31. Shi, H, Liu, K., Xu, A., and Yao, S. Q. (2009) Small molecule microarray-facilitated screening of affinitybased probes (AfBPs) for gamma-secretase. Chem. Commun. 33, 5030-5032
32. Gallizia, A., de Lalla, C, Nardone, E., Santambrogio, P., Brandazza, A., Sidoli, A., and Arosio, P. (1998) Production of a soluble and functional recombinant streptavidin in Escherichia coli. Protein Expr. Purif. 14, 192-196
33. Sano, T. and Cantor, C. R. (1995) Intersubunit contacts made by tryptophan 120 with biotin are essential for both strong biotin binding and biotin-induced tighter subunit association of streptavidin. Proc. Natl. Acad. Sci. USA. 92, 3180-3184
34. Sano, T. and Cantor, C. R. (1990) Expression of a cloned streptavidin gene in Escherichia coli. Proc. Natl. Acad. Sci. USA. 87, 142-146
35. Thompson, L. D. and Weber, P. C. (1993) Construction and expression of a synthetic streptavidin-encoding gene in Escherichia coli. Gene 136, 243-246
36. McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674
37. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763
38. Kawato, T., Mizohata, E., Meshizuka, T., Doi, H, Kawamura, T., Matsumura, H., Yumura, K., Tsumoto, K., Kodama, T., Inoue, T., and Sugiyama, A. (2015) Crystal structure of streptavidin mutant with low immunogenicity. J. Biosci. Bioeng. 119, 642-647
39. Emsley, P., Lohkamp, B., Scott, W. G., and Cowtan, K. (2010) Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501
40. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255
41. Stayton, P. S., Freitag, S., Klumb, L. A., Chilkoti, A., Chu, V., Penzotti, J. E., To, R., Hyre, D., Le Trong, I., Lybrand, T. P., and Stenkamp, R. E. (1999) Streptavidinbiotin binding energetics. Biomol. Eng. 16, 39-44
42. Athappilly, F. K. and Hendrickson, W. A. (1997) Crystallographic analysis of the pH-dependent binding of iminobiotin by streptavidin. Protein Sci. 6, 1338-1342
43. Wilbur, D. S., Hamlin, D. K., Pathare, P. M., and Weerawarna, S. A. (1997) Biotin reagents for antibody pretargeting. Synthesis, radioiodination, and in vitro evaluation of water soluble, biotinidase resistant biotin derivatives. Bioconjug. Chem. 8, 572-584
44. Hytonen, V. P., Maatta, J. A., Niskanen, E. A., Huuskonen, J., Helttunen, K. J., Halling, K. K., Nordlund, H. R., Rissanen, K., Johnson, M. S., Salminen, T. A., Kulomaa, M. S., Laitinen, O. H., and Airenne, T. T. (2007) Structure and characterization of a novel chicken biotin-binding protein A (BBP-A). BMC Struct. Biol. 7, 8
45. Baugh, L., Le Trong, I., Cerutti, D. S., Mehta, N., Gulich, S., Stayton, P. S., Stenkamp, R. E., and Lybrand, T. P. (2012) Second-contact shell mutation diminishes streptavidin-biotin binding affinity through transmitted effects on equilibrium dynamics. Biochemistry 51, 597-607
46. Weber, P. C., Ohlendorf, D. H., Wendoloski, J. J., and Salemme, F. R. (1989) Structural origins of high-affinity biotin binding to streptavidin. Science 243, 85-88
47. Weber, P. C., Wendoloski, J. J., Pantoliano, M. W., and Salemme, F. R. (1992) Crystallographic and thermodynamic comparison of natural and synthetic ligands bound to streptavidin. J. Am. Chem. Soc. 114, 3197-3200
48. Freitag, S., Le Trong, I., Klumb, L., Stayton, P. S., and Stenkamp, R. E. (1997) Structural studies of the streptavidin binding loop. Protein Sci. 6, 1157-1166